WallStreetZenWallStreetZen

NYSE: TAK
Takeda Pharmaceutical Co Ltd Earnings Dates, Reports, Calls

OverviewForecastEarnings
RevenueDividendOwnership
Takeda Pharmaceutical Co earnings were $737.4M for the trailing 12 months ending Dec 31, 2025, with -45.1% growth year over year. The latest TAK earnings report on Dec 31, 2025 announced Q4 2025 earnings of $666.2M, down 949.2% from last quarter. For the last reported fiscal year 2025 ending Mar 31, 2025, TAK reported annual earnings of $722.9M, with -24% growth.

TAK past earnings growth

How has TAK's earnings growth performed historically?

Company
-45.13%
Industry
45.3%
Market
43.96%
TAK's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
TAK's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Market Performance
TAK's earnings growth is slowing... subscribe to Premium to read more.
Accelerating Earnings Growth Performance

TAK earnings history

Current Revenue
$28.7B
Current Earnings
$725.6M
Current Profit Margin
2.5%

TAK Return on Equity

Current Company
1.6%
Current Industry
16.4%
Current Market
31.3%
TAK's Return on Equity (1.6%)... subscribe to Premium to read more.
High Return on Equity Performance

TAK Return on Assets

Current Company
0.8%
Current Industry
6%
TAK is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when TAK announces earnings.

TAK Return on Capital Employed

Current Company
4.45%
Current Industry
12.7%
TAK has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

TAK vs Pharmaceutical Stocks

TickerEBITDAEarningsY/Y EarningsEPS
TAK$8.59B$737.40M-16.20%$0.24
ZTS$4.07B$2.67B+11.88%$6.03
HLN$3.12B$1.87B+3.82%$0.41
TEVA$3.17B$1.41B+34.13%$1.23
VTRS-$395.40M-$3.51BN/A-$3.00
View Top Pharmaceutical Stocks

Takeda Pharmaceutical Co Earnings Reports & History FAQ

What were Takeda Pharmaceutical Co's earnings last quarter?

On TAK's earnings call on Invalid Date, Takeda Pharmaceutical Co (NYSE: TAK) reported Q4 2025 earnings per share (EPS) of $0.21, up 339.58% year over year. Total TAK earnings for the quarter were $666.24 million. In the same quarter last year, Takeda Pharmaceutical Co's earnings per share (EPS) was $0.05.

If you're new to stock investing, here's how to buy Takeda Pharmaceutical Co stock.

Is Takeda Pharmaceutical Co profitable or losing money?

As of the last Takeda Pharmaceutical Co earnings report, Takeda Pharmaceutical Co is currently profitable. Takeda Pharmaceutical Co's net profit (also called net income) for the twelve months ending Dec 31, 2025 was $725.56 million, a 45.47% decrease year over year.

What was TAK's earnings growth in the past year?

As of Takeda Pharmaceutical Co's earnings date in Invalid Date, Takeda Pharmaceutical Co's earnings has grown -45.13% year over year. This is 90.43 percentage points lower than the US Drug Manufacturers - Specialty & Generic industry earnings growth rate of 45.3%. TAK earnings in the past year totalled $737.40 million.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.